Valproic acid enhances pamidronate-sensitized cytotoxicity of Vδ2


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 01 07 2020
revised: 23 07 2020
accepted: 08 08 2020
pubmed: 21 8 2020
medline: 28 5 2021
entrez: 21 8 2020
Statut: ppublish

Résumé

Therapeutic options for Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative diseases (PTLD) are currently limited, accompanying with some off-target toxicities. We previously demonstrated that early recovery of Vδ2

Identifiants

pubmed: 32818705
pii: S1567-5769(20)32192-5
doi: 10.1016/j.intimp.2020.106890
pii:
doi:

Substances chimiques

Valproic Acid 614OI1Z5WI
Pamidronate OYY3447OMC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106890

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no potential conflicts of interest.

Auteurs

Haitao Gao (H)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Ruoyang Liu (R)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Ning Wu (N)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Nanfang Hospital, Southern Medical University, Guangzhou, China.

Xiao-Dong Mo (XD)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Wei Han (W)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

Xin Huang (X)

Department of pathology, School of medical Science, Peking University Health Science Center, Beijing, China.

Xiao-Jun Huang (XJ)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Nanfang Hospital, Southern Medical University, Guangzhou, China.

Jiangying Liu (J)

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address: bjmuljy@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH